New research indicates that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end traditional lifestyle programs.
Research printed in a prominent medical journal points out that while obese people often shed about a fifth of their total mass while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Users using these treatments need to be aware of the risk of fast weight regain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of regain means a reversion to pre-treatment weight within about a year and a half.
Comparing Therapies
The analysis, which looked at 37 of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Scientists point out that people who shed pounds through lifestyle changes alone generally see a slower weight regain—around 100 grams monthly—post-intervention.
The Reason for the Quick Rebound
Doctors propose the mode of action of the drugs explains the accelerated rebound.
These medications imitate a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in hunger is unsuppressed, making overeating a significant risk."
A Lifelong Condition?
The NHS advise the jabs for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
Professionals say that, considering the high risk of relapse, the therapy should be considered life-long.
This view is supported by drug manufacturers, who say that the results "emphasize the long-term character of obesity," similar to managing diseases like hypertension.
Patient Testimonies
Users who have stopped the jabs describe a powerful resurgence of appetite.
"It felt as if a switch activating and you become extremely hungry," described an individual.
The struggle is compounded if patients have not adopted lasting lifestyle or habit changes during treatment.
Growing Use
Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is greater among females compared to males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Finally, clinicians emphasize that while these medications are effective agents for weight loss, they are not a standalone fix and lasting health benefits relies on ongoing lifestyle support.
